In Brief: Guidant/EndoVascular Technologies
This article was originally published in The Gray Sheet
Guidant/EndoVascular Technologies: EVT shareholders approve Guidant's proposed acquisition of the company, Guidant reports Dec. 19. Announced Oct. 6, the $170 mil. deal calls for an exchange of 0.3154 shares of Guidant for each EVT share ("The Gray Sheet" Oct. 13 I&W-1). Guidant says it issues roughly 2.7 mil. shares in connection with the purchase. EVT CEO Jim Fitzimmons is named a Guidant senior VP and general manager of the company's Cardiac & Vascular Surgery Group, formerly known as the Minimally Invasive Systems Group...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.